Bio tech company updates — 11/8/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korea's biotech sector is seeing a surge in strategic partnerships and high-level policy discussions as the industry braces for significant shifts in funding and global investment landscapes. Hanmi Pharmaceutical and Samsung Securities have announced a new initiative to support biotech startups, while experts debate the necessity of transitioning from government grants to direct investment models. Meanwhile, the sector faces increasing pressure from China's long-term funding strategies and potential regulatory hurdles from US outbound investment rules.
Headline: Korean Biotechs Seek New Funding Models Amid Global Investment Shifts
Key Findings
- Strategic Partnership for Startups: Hanmi Pharmaceutical (128940.KS) and Samsung Securities are collaborating to help promising biotech startups attract investment and find business partners, with a "Bio Innovation Day" scheduled for November 27.
- Policy & Funding Critique: Industry experts and policymakers are debating the effectiveness of Korea's current biotech support system, with calls to shift R&D support from grants to investment models and establish a dedicated "biotech czar" to unify data and budgets.
- Global Competitive Pressure: Recent discussions highlight a growing gap between South Korea's biohealth R&D efforts and China's long-term funding strategy, with China's bio exports significantly outpacing Korea's.
- Regulatory Risks: The proposed US COINS Act could complicate China biotech deals, prompting Korean firms to reassess their global partnership strategies.
Details
Strategic Alliances and Startup Support
In a move to bolster the domestic biotech ecosystem, Hanmi Pharmaceutical has joined forces with Samsung Securities. This partnership aims to create a bridge between early-stage biotech startups and capital markets. The collaboration will culminate in the "Bio Innovation Day" on November 27, where startups will have opportunities to connect with investors and potential business partners.
The Call for Structural Policy Reform
The industry is facing critical scrutiny regarding its governance and funding structures. Recent reports indicate that "policy no-shows" and a lack of unified leadership have clouded the country's bio push. Experts are urging the government to appoint a dedicated biotech leader ("biotech czar") to oversee unified data and budgets, arguing that this control tower is essential for maintaining momentum.
Furthermore, there is a strong consensus among health sector experts that the government must shift its research and development (R&D) support model. The prevailing view is that traditional grant-based support is insufficient for the next growth phase; instead, a shift toward direct investment models is recommended to better align public resources with market realities.
Global Competition and Regulatory Headwinds
The competitive landscape is intensifying, particularly with China. Analysis suggests that while China accelerates its biotech sector through long-term funding commitments, South Korea risks a "support gap." Data indicates that China’s bio exports ($139.4B) vastly exceed South Korea’s ($14.7B), highlighting an urgent need for more sustained, long-term R&D investment in Korea.
Additionally, geopolitical factors are influencing deal-making. At the Bioplus-Interphex Korea 2026 conference, it was noted that the proposed U.S. COINS Act (Outbound Investment National Security) could make direct investment and newco formation out of China "somewhere between hard and impossible." This regulatory uncertainty is forcing Korean biotech firms to carefully evaluate their international partnerships and investment routes.
Innovation Showcases
Despite these challenges, innovation continues to thrive. The Gangneung bio showcase recently highlighted breakthroughs in AI-driven drug design, polar-sourced materials, and biomimetic technology, demonstrating the sector's capacity for diverse technological advancement.
Sources
Hanmi, Samsung Securities Team Up to Back Biotech Startups - Seoul Economic Daily
Korean Biotechs Unveil Lymphoma Trial Data at U.S. Blood Cancer Meeting - Seoul Economic Daily
Korea showcases biotech and natural product breakthroughs at Gangneung conference - CHOSUNBIZ
biz.chosun.com
biz.chosun.com
biz.chosun.com
health.chosun.com
biz.chosun.com
chosun.com
bioworld.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
